Thyroid cancer with cranial metastasis in a pregnant woman is very rare. In the literature, most cases are diagnosed early from neurogenic signs or symptomatic thyroid gland. Pregnancy also contributes to a hesitation toward early surgical and medical treatments. We reported a scalp tumor in a physically healthy 37-year-old pregnant female with a follicular thyroid carcinoma (FTC) with lung, bone and cranial metastasis in initial presentation. Silent neurogenic and physical examinations make an early diagnosis very challenging. Resection of scalp and intracranial tumor, a thyroidectomy, post-operative radioactive iodine therapy and tyrosine kinase inhibitors were employed as treatment. The scalp tumor was confirmed as a metastatic follicular thyroid carcinoma via positive immunoreactivity for thyroglobulin and thyroid transcription factor 1 in tumor cells. Blood examination revealed an elevated thyroglobulin level (>5335 ng/mL). The patient was discharged without any neurological deficit. An asymptomatic scalp tumor in a pregnant woman with a normal thyroid disease history needs differential diagnosis from intracranial origin. Rapid progression and an elevated thyroglobulin level are the indicators that further image study is needed. Aggressive surgical excision of resectable thyroid gland and metastatic tumor are essential for a longer survival rate. There is nothing to indicate that a post-partum operation will worsen prognosis. LEARNING POINTS: Follicular thyroid cancer with cranial metastasis in initial presentation can be asymptomatic.Follicular thyroid cancer with cranial metastasis in a pregnant woman can be treated after delivery.Rapid enlargement of scalp tumor is indicated for further image study even in a patient without any neurological deficit.
Thyroid cancer with cranial metastasis in a pregnant woman is very rare. In the literature, most cases are diagnosed early from neurogenic signs or symptomatic thyroid gland. Pregnancy also contributes to a hesitation toward early surgical and medical treatments. We reported a scalp tumor in a physically healthy 37-year-old pregnant female with a follicular thyroid carcinoma (FTC) with lung, bone and cranial metastasis in initial presentation. Silent neurogenic and physical examinations make an early diagnosis very challenging. Resection of scalp and intracranial tumor, a thyroidectomy, post-operative radioactive iodine therapy and tyrosine kinase inhibitors were employed as treatment. The scalp tumor was confirmed as a metastatic follicular thyroid carcinoma via positive immunoreactivity for thyroglobulin and thyroid transcription factor 1 in tumor cells. Blood examination revealed an elevated thyroglobulin level (>5335 ng/mL). The patient was discharged without any neurological deficit. An asymptomatic scalp tumor in a pregnant woman with a normal thyroid disease history needs differential diagnosis from intracranial origin. Rapid progression and an elevated thyroglobulin level are the indicators that further image study is needed. Aggressive surgical excision of resectable thyroid gland and metastatic tumor are essential for a longer survival rate. There is nothing to indicate that a post-partum operation will worsen prognosis. LEARNING POINTS: Follicular thyroid cancer with cranial metastasis in initial presentation can be asymptomatic.Follicular thyroid cancer with cranial metastasis in a pregnant woman can be treated after delivery.Rapid enlargement of scalp tumor is indicated for further image study even in a patient without any neurological deficit.
Thyroid cancer is the second most common cancer diagnosed during pregnancy. Most cases
are diagnosed early from physical examination, with symptoms being a swollen neck and/or
palpable lymph nodes. Thyroid cancer with central nervous system metastasis rarely
occurs, and it accounts for only about 1% of patients. However, the incidence rate of
thyroid cancer with brain metastasis as an initial presentation has not been described
well. Few case reports have been written, but either positive physical and neurological
signs or a malignant thyroid disease can be identified during history-taking. To our
knowledge, thyroid carcinoma with multiple metastases in initial presentation in a
pregnant woman, whose thyroid medical history is benign, has never been reported.We have reported on this rare case in this article and reviewed the surrounding
literature. We also have discussed the clinical dilemmas present and whether a patient
should be treated after delivery or not.
Case presentation
A 37-year-old pregnant woman came to our clinic due to a left scalp tumor that was
palpable when she washed her hair. Her medical history includes that her gestational age
(GA) at the time was 21 weeks and that she had a thyroid follicular adenoma before which
was treated with right-side subtotal thyroidectomy in a separate local hospital five
years earlier. Before she discovered this oval-shaped tumor on her left scalp, there
were no symptomatic signs, such as headache, pain, neck mass or chronic cough.
Clinically, the scalp tumor measured about 3.8 × 1.0 cm with
sharp margins and was movable. As there are no history of thyroid carcinoma and no
neurological deficit, pre-operative brain MRI does not meet cost-effectiveness (MRI is
not covered by our health insurance system). Brain CT is also contra-indicated in a
pregnant woman. Therefore, the only image study is ultrasonography before operation. The
sonography revealed a homogenous tumor in the subcutaneous layer with clear margins. We
followed up with this case until the patient delivered a healthy full-term infant.During the third trimester, the tumor gradually increased to
7.0 × 7.0 in size. The tumor was soft and elastic with normal hair
distribution and skin color. There was no neurological sign except left lower back pain
found after delivery of the baby. There is no change in mental status, no headache, no
facial nerve palsy, no focal weakness, no hemiparesis, no nausea and vomiting and no
sensation disturbance.A scheduled excisional biopsy of the tumor under general anesthesia was arranged after
her delivery. A smooth dissection was performed above the galea plane, but
hypervascularity with some engorged vessels were encountered around the base of the
tumor (Fig. 1A). After resection, the scalp tumor
with left parietal bone invasion was highly suspected to be correlated with malignant
distant metastasis (Fig. 1B, C and D). The final
pathologic report confirmed the diagnosis of a follicular carcinoma of thyroid origin
(Fig. 2).
Figure 1
First stage of surgery for left scalp tumor. Smooth plane can be dissected
above galea plane, but hypervascularity with some engorged vessels were
encountered around the base of tumor (A). One
7.0 × 7.0 cm tumor was resected. The surface of
tumor (B) was smooth, but some necrotic tissue and bony fragment were
identified from basal view (C). Skull bone bony defect highly suggests
intracranial origin of this tumor (D).
Figure 2
Frozen section of scalp tumor revealed that there are abundant cube-shaped
cells accompanied with light eosinophilic colloid within follicles (H&E
stain, 200×).
First stage of surgery for left scalp tumor. Smooth plane can be dissected
above galea plane, but hypervascularity with some engorged vessels were
encountered around the base of tumor (A). One
7.0 × 7.0 cm tumor was resected. The surface of
tumor (B) was smooth, but some necrotic tissue and bony fragment were
identified from basal view (C). Skull bone bony defect highly suggests
intracranial origin of this tumor (D).Frozen section of scalp tumor revealed that there are abundant cube-shaped
cells accompanied with light eosinophilic colloid within follicles (H&E
stain, 200×).Lack of a well-prepared image study was the drawback in our study. Both family and
doctors expected the surgery to be a minor one, but it was not. During the first
operation, blood loss was about 1500 mL. A neurosurgeon was also not on stand-by
initially. The pathologist could confirm the thyroid carcinoma metastasis via frozen
section. Lack of an image study also made it difficult for the neurosurgeon to identify
the true lesions because the operative field had massive oozing. We could not perform
craniotomy first as we had to explain the severity of disease to the family and let the
neurosurgeon come to a better decision after the results from permanent pathology and
image reports were available.General surgical consultations accompanying malignancy systemic evaluation were
obtained. Contrast-enhanced magnetic resonance imaging (MRI) revealed intracranial
heterogenous, osteolytic and extra-axial mass located at left parietal bone area (Fig. 3), and it measured
7.3 × 6.0 × 7.0 cm in size. Thyroid
sonography could not detect any mass lesions on either side. Free T4 was
0.43 ng/dL (normal: 0.54–1.40), free T3 was 64.49 ng/dL (normal:
70–170), thyroid-stimulating hormone was 0.47 U/L (normal:
0.34–5.60) and thyroglobulin was elevated to above 5335 ng/mL (normal:
<55). A bone scan and a positron emission tomography scan revealed multiple bone
metastases on the thoracic, lumbar spine, ilium and sacrum bones (Fig. 4A). In a chest CT scan, bilateral lung metastases were also
identified.
Figure 3
Contrast-enhanced magnetic resonance imaging (MRI) with contrast after
first-stage scalp tumor removal. Horizontal (A), coronal (B) and sagittal (C)
view revealed one heterogenous intracranial mass lesion with destroying left
parietal and occipital bone skull bone.
Figure 4
Bone scan revealed multiple bone metastases on thoracic, lumbar spine, ilium
and sacrum bone.
Contrast-enhanced magnetic resonance imaging (MRI) with contrast after
first-stage scalp tumor removal. Horizontal (A), coronal (B) and sagittal (C)
view revealed one heterogenous intracranial mass lesion with destroying left
parietal and occipital bone skull bone.Bone scan revealed multiple bone metastases on thoracic, lumbar spine, ilium
and sacrum bone.After serial systemic evaluation, the patient underwent craniotomy surgery for the
resection of the metastatic tumor. Intra-operatively, the metastatic tumor invaded the
dura and arachnoid membrane without brain parenchyma involvement. Brain tissue was
decompressed after ablation of the tumor, and brain tissue fully expanded without any
tissue loss.Immunohistochemistry showed positivity for thyroglobulin and thyroid transcription
factor 1 (TTF-1), which established strong evidence for metastatic thyroid carcinoma
origin (Fig. 5) (2). Two weeks after the craniectomy, however, a left thyroid lobectomy
revealed that there was no residual follicular carcinoma inside.
Figure 5
Positive findings for thyroglobulin (A) and thyroid transcription factor 1 (B)
confirm the diagnosis of metastatic thyroid carcinoma.
Positive findings for thyroglobulin (A) and thyroid transcription factor 1 (B)
confirm the diagnosis of metastatic thyroid carcinoma.The post-operative course went smoothly. Her muscle power was 5 in each side, and she
was discharged on her own accord without nerve palsy or hemiplegia. She received
levothyroxine therapy 150 µg per day, and her free T4 level is within
normal range. After post-operative recovery, a dose of 200 millicuries (mCi) of
radioactive iodine (131I) (Fig. 6) and tyrosine
kinase inhibitor were prescribed for her. Five months after the operation, she still
survives and follows up regularly.
Figure 6
I131 whole body scan revealed increased radioactivity over bilateral lungs,
upper back and pelvic bone area.
I131 whole body scan revealed increased radioactivity over bilateral lungs,
upper back and pelvic bone area.
Discussion
To our knowledge, this is the first case where a silent multiple metastatic follicular
thyroid carcinoma (FTC) presented in a pregnant woman without previous related medical
history. The only clinical clue in this case was the patient’s history of benign
follicular adenoma (FA) informed at a local clinic five years. The patient received
right subtotal thyroidectomy at that time. We asked the local hospital to review the
initial diagnosis. However, the gross specimen is missing and the remaining pathology
slide still contributes to the diagnosis of thyroid adenoma. The erroneous diagnosis is
probably due to the limitation of pathological diagnosis. From the point of view of
histology, a minimally invasive follicular thyroid carcinoma is difficult to be
distinguished from a follicular adenoma of the thyroid. It is still unclear as to
whether or not FTC arises from pre-existing FA or not. The diagnosis of minimally
invasive FTC entirely depends on the demonstration of limited vascular invasion and/or
localized tumor invasion through its capsule. If the protrusion of thyroid capsule is
not just cut and identified, the FTC will be considered as thyroid adenoma. Lee
et al. have reported the average interval between the first
diagnosis of thyroid cancer and intracranial metastasis was 50.5 months (range,
0–150 months) (3). Therefore, the
patient’s past medical information ought to be interpreted to mean that the
correct pathological diagnosis at that time should be follicular thyroid carcinoma. In
the literature review, there has been one case reported where a brain metastatic
follicular thyroid carcinoma occurred without neurological signs in a 65-year-old female
12 years after initial presentation (2).
Intracranial metastasis accounts for about 1% of thyroid malignancies (4). The fact that this case was a soft and elastic
scalp tumor in a pregnant woman with silent neurological expression made the clinician
not be alert to differentiate the possibility of the tumor’s intracranial
origin.Distant metastasis (DM) is categorized into two groups: DM at initial presentation and
DM after initial treatment (5). Older females
are the predominant patient group in DM. The primary diagnosis of distant metastasis
thyroid cancer is very rare, ranging from 1% to 7.2% (5, 6, 7). Due to its rarity, pre-operative diagnosis of DM is very
challenging (8), especially in our case.
Pregnancy at a GA of 21 weeks and limited medical history made the pre-operative
diagnosis much more difficult. Thyroid cancer is the second most common newly diagnosed
cancer during pregnancy (1). Some authors have
correlated the progression of malignancy to the binding between human chorionic
gonadotropin (β-HCG) and TSH receptors. This hypothetical mechanism probably
explains the rapid progression of the tumor in our case (9). Indeed, the tumor grew two times in size from
3.8 × 1.0 cm to 7.0 × 7.0 cm
during our patient’s pregnancy. On the other hand, in a meta-analysis review,
Negri et al. could not conclude if a strong association between
reproductive factors and thyroid cancer exist. Only younger pregnant women diagnosed
with papillary thyroid cancer may have higher risks (10). Some claim that estrogen-binding receptors could be identified on
thyroid tumors (11), but this remains suspect
as the results could not be replicated (12).
Clarity on the mechanism between pregnancy and thyroid follicular carcinoma still
requires more studies.This huge cranial metastatic tumor, however, did not have any neurological signs. To our
knowledge, the only patient in the literature who had a similar clinical presentation
without any neurological anomalies, had her tumor, like our patient, confined within the
dura (2). The patient’s lower back pain
can be explained by pelvic bone metastasis, but this sign can be confused as pregnancy
related. The most common DM is lung, followed by bone, and then brain (3, 5).
Recently, the overall survival rate from the data, which shows great improvement over
Haq et al., has been estimated at 83.8% and 72.1% for 5 and 10 years
respectively (5). Cranial metastasis is regarded
as a poor prognostic factor (3), whereas cranial
metastasis without brain involvement has been seldom reported.Optimal treatments for thyroid malignancy with metastasis in pregnancy are still not
standardized due to its rarity. Maternal and neonatal morbidity and complications are
the major concern (9). FTC is the second most
common thyroid cancer after papillary thyroid carcinoma (PTC) during pregnancy, and the
prevalence rate is about 14 per 100 000 live births (1). Differing from the lymphatic route in PTC, FTC tends to
metastasize via angioinvasion with an aggressive pattern. When compared with PTC, FTC
displays a shorter period until intracranial metastasis (3). The reported average survival for patients with follicular
carcinoma and brain metastasis is 8.3 months (7). However, pregnancy has been found to have no impact on the prognosis of
women with thyroid cancer. There were no correlations found between maternal and
neonatal complications in the study by Yasmeen’s et al. The
survival rate also shows no significant decrease in pregnant women compared to similarly
aged non-pregnant women (9). Therefore, if a
correct diagnosis of brain metastasis from thyroid origin is identified, as in our case,
the pregnant woman’s tumor progression still needs to be observed until her
delivery. Our case in particular shows that further image studying can strongly indicate
a rapidly progressive scalp tumor found during pregnancy, even a tumor without
neurological symptoms.Prognostic factors in previous studies include the male gender, old age, poorly
differentiated histological variants, incomplete surgical resection of a primary tumor,
multiple metastasis and poor response to radioactive iodine (RAI) treatment (3, 5, 13). The independent factor improving survival
rate is surgical resection to achieve complete local control (3, 5, 7). Removal of the entire thyroid and possible metastasectomy are
recommended because they will decrease the tumor loading and the amount of radioactive
iodine (RAI) therapy needed (3, 7). RAI therapy is only beneficial for uptake scan
positive in brain metastasis. Unfortunately, there are few cases resistant to
radioactive iodine therapy in distant metastatic thyroid cancer. As the reported uptake
rate of brain metastasis ranges only from 17% to 23% (7), adjuvant whole-brain radiation therapy, stereotactic radiosurgery,
cytotoxic chemotherapy, biotherapy and tyrosine kinase inhibitors should be considered
for patients resistant to RAI therapy. Doxorubicin is the most frequent chemotherapy
agent, but only partial response rate of 22% can be achieved (14). Recently, tyrosine kinase inhibitors was applied to these
kinds of refractory cases and showed its potential in treatments. Dowson et
al. (15) report two cases with
4-year disease-free survival after sunitinib therapy. In the case series of M.D.
Anderson Cancer Center (16), they report
partial remission rate of 20%, durable response rate of 66% and a clinical benefit rate
of 80%. Lung metastasis is a more favorable site, but bony metastasis responds poorly.
During the post-operative period, thyroglobulin (TG) level is effective for detecting
distant metastasis in thyroid cancer patients, especially in FTC with brain metastasis
(3). The dramatically increased TG level in
our case is another possible early detector for diagnosing before operation.
Summary
In the above we have reported a rare case with diffuse metastatic follicular carcinoma
in a pregnant woman. This silent scalp tumor case forces us to confront possible
malignancy even in patients with normal thyroid disease history. Rapid progression and
an elevated thyroglobulin level are indicators of the need for further image study.
Aggressive surgical excision of cranial metastasis should only be performed after
delivery.
Declaration of interest
All authors certify that we have no affiliations with or involvement in any organization
or entity with any financial interest (such as honoraria; educational grants;
participation in speakers’ bureaus; membership, employment, consultancies, stock
ownership or other equity interest; and expert testimony or patent-licensing
arrangements) or non-financial interest (such as personal or professional relationships,
affiliations, knowledge or beliefs) in the subject matter or materials discussed in this
manuscript.
Funding
None of the authors have any financial or personal relationships with persons or
organizations that could inappropriately influence the study.
Authors: S Yasmeen; R Cress; P S Romano; G Xing; S Berger-Chen; B Danielsen; L H Smith Journal: Int J Gynaecol Obstet Date: 2005-10 Impact factor: 3.561
Authors: Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: Robert R McWilliams; Caterina Giannini; Ian D Hay; John L Atkinson; Scott L Stafford; Jan C Buckner Journal: Cancer Date: 2003-07-15 Impact factor: 6.860
Authors: Artanto Wahyono; Ery Kus Dwianingsih; Widya Surya Avanti; Roby Cahyono; Rosa Mandasari; Sumadi Lukman Anwar Journal: Ann Med Surg (Lond) Date: 2022-02-04